Predictive oncology reports year end 2022 financial results and provides business update

Eagan, minn., march 21, 2023 (globe newswire) -- predictive oncology inc. (nasdaq: poai), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, clinical laboratory improvement amendments (clia) laboratory and good manufacturing practices (gmp) facility, to accelerate oncology drug discovery and enable drug development, today reported financial and operating results for the year ended december 31, 2022, and provided a corporate update. the company reported a net loss of $25.7 million on total net revenue of $1.5 million for the full year.
POAI Ratings Summary
POAI Quant Ranking